"How Biomarkers Transform Genetic Diagnostics: A Success Story With Fabry Disease"
Biomarkers play an essential role in the diagnosis of rare diseases – ending patients’ diagnostic odysseys and accelerating personalized treatment.
Throughout the on demand CentoTalk, Dr. Tobias Boettcher provides an overview of how biomarkers play an essential role in early diagnosis, prediction, and therapeutic monitoring for Fabry disease patients. At the end, he dives into in-depth questions with colleagues from the field – opening up a platform for discussion and collaboration to advance Fabry care.
- Diagnostic Difficulties for Fabry Disease
- Biomarkers in the Diagnostic Setting
- Lyso-Gb3: Advantages and Drawbacks
- Clinical Cases and Lessons for the Future
- Advanced Diagnostics and Precision Medicine
Tobias Böttcher, MD
Tobias Boettcher completed his internship in Neurology at the Dept. of Neurology, University of Rostock, Germany. During this time, he received a research grant from the German Academy of Natural Sciences Leopoldina, with projects at the Dept. of Physiology/Pharmacology, Karolinska Institute, and the Dept. of Neurology, University of Goettingen. In 2005, Dr. Boettcher received his Board Certification in Neurology, and subsequently worked for four years as a Registrar Neurologist at the Dept. of Neurology, Dietrich-Bonhoeffer-Hospital, Neubrandenburg.
Since September 2017, Dr. Boettcher has worked as a Clinical Neurologist at the Outpatient Medical Center of the Johanna-Odebrecht-Stiftung, Greifswald, at the specialized Outpatient Department for Neurogenetic Diseases and LSDs. Dr. Boettcher has co-authored 48 peer-reviewed scientific publications (19 in the scope of LSDs). Since 1997, he has developed vast experience in the field of LSDs through his work in patient care (outpatient departments), basic research (Neurogenetic Laboratory, University of Rostock), and diagnostics (CENTOGENE).